Skip to main content
AGEN
NASDAQ Life Sciences

Agenus 从与 Zydus 的合作中获得首个 2000 万美元里程碑付款，用于药物生产

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$3.38
Mkt Cap
$114.948M
52W Low
$1.38
52W High
$7.34
Market data snapshot near publication time

summarizeSummary

Agenus 触发了其与 Zydus Lifesciences 战略合作下的首个 2000 万美元应计付款。本付款专门用于生产和与其实验性药物 botensilimab 和 balstilimab 相关的关键化学、制造和控制活动。该合作于 1 月份完成，为 Agenus 提供了长期的美国生物制剂制造能力，包括最高 5000 万美元的潜在应计付款。对于一家市值约为 1.15 亿美元的临床阶段免疫肿瘤公司来说，这 2000 万美元的非稀释现金流入具有高度的物质性，显著增强了其财务状况，并支持其关键药物候选物向监管批准推进。投资者应关注该合作中的进一步里程碑付款以及 botensilimab 和 balstilimab 的临床和监管进展。

在该公告发布时，AGEN的交易价格为$3.38，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.1亿。 52周交易区间为$1.38至$7.34。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed AGEN - Latest Insights

AGEN
Apr 20, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Agenus Seeks Shareholder Approval for Significant Equity Plan Expansion and Option Repricing
Sentiment: Negative
View Wiseek Article
AGEN
Apr 17, 2026, 4:46 PM EDT
Source: Reuters
Importance Score:
9
Agenus's Botensilimab/Balstilimab Combo Fails Primary Endpoint in Phase II Gastroesophageal Cancer Study
Sentiment: Negative
View Wiseek Article
AGEN
Mar 26, 2026, 8:33 AM EDT
Source: Wiseek News
Importance Score:
8
Federal Court Dismisses Securities Class Action Against Agenus
Sentiment: Positive
View Wiseek Article
AGEN
Mar 26, 2026, 8:24 AM EDT
Filing Type: 8-K
Importance Score:
8
Agenus Secures Dismissal of Securities Class Action Lawsuit
Sentiment: Positive
View Wiseek Article
AGEN
Mar 16, 2026, 5:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Agenus Reports Going Concern Doubt, Major Partnership Terminations, and Critical Zydus Deal
Sentiment: Negative
View Wiseek Article
AGEN
Mar 16, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Agenus Advances Lead Immunotherapy to Global Phase 3, Secures $20M Payment, and Reports Strong 2025 Results
Sentiment: Positive
View Wiseek Article
AGEN
Mar 16, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Key Cancer Drug BOT+BAL Advances to Phase 3, Early Access Programs Generate $4.2M Revenue
Sentiment: Positive
View Wiseek Article
AGEN
Mar 10, 2026, 3:45 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Agenus Secures First $20M Milestone Payment from Zydus Collaboration for Drug Production
Sentiment: Positive
View Wiseek Article
AGEN
Jan 23, 2026, 8:57 AM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Strategic Partner Zydus Acquires 5.9% Stake in Agenus at Significant Premium
Sentiment: Positive
View Wiseek Article
AGEN
Jan 16, 2026, 8:25 AM EST
Filing Type: 8-K
Importance Score:
9
Agenus Secures $91M Capital and Strategic Manufacturing Capacity via Zydus Collaboration
Sentiment: Positive
View Wiseek Article